Bookbuilding IPO | ₹1,551 Cr | Listed at BSE, NSE | Fri, Aug 4, 2023 - Tue, Aug 8, 2023
Concord Biotech IPO is a book build issue of ₹1,550.52 crores. The issue is entirely an offer for sale of 2.09 crore shares of ₹1,550.52 crore.
Concord Biotech IPO bidding started from Aug 4, 2023 and ended on Aug 8, 2023. The allotment for Concord Biotech IPO was finalized on Aug 11, 2023. The shares got listed on BSE, NSE on Aug 18, 2023.
Concord Biotech IPO price band is set at ₹741 per share. The lot size for an application is 20. The minimum amount of investment required by an retail is ₹14,820 (20 shares) (based on upper price). The lot size investment for sNII is 14 lots (280 shares), amounting to ₹2,07,480, and for bNII, it is 68 lots (1,360 shares), amounting to ₹10,07,760.
The issue includes a reservation of up to 10,000 shares for employees offered at a discount of ₹70.00 to the issue price.
Kotak Mahindra Capital Co.Ltd. is the book running lead manager and MUFG Intime India Pvt.Ltd. is the registrar of the issue.
Refer to Concord Biotech IPO RHP for detailed Information.
IPO Open
Fri, Aug 4, 2023
IPO Close
Tue, Aug 8, 2023
Issue Price
₹741 per share
Market Cap (Pre-IPO)
₹7,752.06 Cr
| IPO Date | 4 to 8 Aug, 2023 |
| Listed on | Fri, Aug 18, 2023 |
| Face Value | ₹1 per share |
| Price Band | ₹705 to ₹741 |
| Issue Price | ₹741 per share |
| Lot Size | 20 Shares |
| Sale Type | OFS only |
| Issue Type | Bookbuilding IPO |
| Listing At | BSE, NSE |
| Employee Discount | ₹70.00 |
| Total Issue Size | 2,09,25,652 shares (agg. up to ₹1,551 Cr) |
| Offer for Sale | 2,09,25,652 shares of ₹1 (agg. up to ₹1,551 Cr) |
| Share Holding Post Issue | 10,46,16,204 shares |
| BSE Script Code / NSE Symbol | 543960 / CONCORDBIO |
| ISIN | INE338H01029 |
Concord Biotech IPO offers total 2,09,25,652 shares. Out of which 1,04,57,825 (49.98%) allocated to QIB, 41,83,130 (19.99%) allocated to QIB (Ex- Anchor), 31,37,348 (14.99%) allocated to NII 73,20,479 (34.98%) allocated to RII and 62,74,695 (29.99%) allocated to Anchor investors.
| Investor Category | Shares Offered | Max Allottees |
|---|---|---|
| QIB Shares Offered | 1,04,57,825 (49.98%) | NA |
| − Anchor Investor Shares Offered | 62,74,695 (29.99%) | NA |
| − QIB (Ex. Anchor) Shares Offered | 41,83,130 (19.99%) | NA |
| NII (HNI) Shares Offered | 31,37,348 (14.99%) | NA |
| − bNII > ₹10L | 20,91,565 (10.00%) | 7,469 |
| − sNII < ₹10L | 10,45,783 (5.00%) | 3,734 |
| Retail Shares Offered | 73,20,479 (34.98%) | 3,66,023 |
| Employee Shares Offered | 10,000 (0.05%) | NA |
| Total Shares Offered | 2,09,25,652 (100.00%) |
Investors can bid for a minimum of 20 shares and in multiples thereof.
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | 1 | 20 | ₹14,820 |
| Retail (Max) | 13 | 260 | ₹1,92,660 |
| S-HNI (Min) | 14 | 280 | ₹2,07,480 |
| S-HNI (Max) | 67 | 1,340 | ₹9,92,940 |
| B-HNI (Min) | 68 | 1,360 | ₹10,07,760 |
Concord Biotech IPO raises ₹464.95 crore from anchor investors. Concord Biotech IPO Anchor bid date is August 3, 2023.
📝 Anchor Investors Letter (PDF)
| Bid Date | Thu, Aug 3, 2023 |
| Shares Offered | 62,74,695 |
| Anchor Portion (₹ Cr.) | 464.95 |
| Anchor lock-in period end date for 50% shares (30 Days) | Sun, Sep 10, 2023 |
| Anchor lock-in period end date for remaining shares (90 Days) | Thu, Nov 9, 2023 |
| Application Category | Maximum Bidding Limits | Bidding at Cut-off Price Allowed |
|---|---|---|
| Only RII | Up to Rs 2 Lakhs | Yes |
| Only sNII | Rs 2 Lakhs to Rs 10 Lakhs | No |
| Only bNII | Rs 10 Lakhs to NII Reservation Portion | No |
| Only employee | Yes | |
| Employee + RII/NII |
|
Yes for Employee and RII/NII |
Incorporated in 1984, Concord Biotech Limited is an India-based R&D-driven biopharma company. The company is ranked among the leading global developers and manufacturers of select fermentation-based APIs across immunosuppressants and oncology in terms of market share, based on volume in 2022.
Concord Biotech has a Global presence. They are supplying their products to over 70 countries including the USA, India, Europe, and Japan.
The company manufactures Active Pharmaceutical Ingredients (API) through fermentation & semi-synthetic process and finished formulations. It started with a single product and has grown to become a wide-spectrum solution provider.
Concord manufactures fermentation and semi-synthetic-based products in therapeutic segments such as Immunosuppressants, Anti-bacterial, Oncology, Antifungals & others. This wide range of products has attracted customers across the globe. Concord also has a robust pipeline of products under development.
| Period Ended | 31 Mar 2023 | 31 Mar 2022 | 31 Mar 2021 |
|---|---|---|---|
| Assets | 1,513.98 | 1,312.80 | 1,182.55 |
| Total Income | 888.48 | 736.35 | 630.75 |
| Profit After Tax | 240.08 | 174.93 | 234.89 |
| NET Worth | 1,290.00 | 1,103.22 | 999.37 |
| Total Borrowing | 31.24 | 60.59 | 86.35 |
| Amount in ₹ Crore | |||
| KPI | |
|---|---|
| ROE | 20.06% |
| ROCE | 24.27% |
| RoNW | 20% |
| PAT Margin | 28.14% |
| Pre IPO | Post IPO | |
|---|---|---|
| EPS (₹) | 20.79 | |
| P/E (x) | 32.29 | |
| Promoter Holding | 44.08% | 44.08% |
| Market Cap | ₹7,752.06 Cr. |
The Concord Biotech IPO is subscribed 24.87 times on August 8, 2023 7:02:00 PM (Day 3). The public issue subscribed 3.78 times in the retail category, 67.67 times in the QIB category, and 16.99 times in the NII category. Check Day by Day Subscription Details (Live Status)
| Category | Subscription (times) | Shares Offered | Shares bid for |
|---|---|---|---|
| QIB | 67.67 | 41,83,130 | 28,30,64,540 |
| NII | 16.99 | 31,37,348 | 5,33,05,680 |
| bNII (bids above ₹10L) | 19.3 | 20,91,565 | 4,03,68,000 |
| sNII (bids below ₹10L) | 12.37 | 10,45,783 | 1,29,37,680 |
| Retail | 3.78 | 73,20,479 | 2,76,82,480 |
| Employee | 24.48 | 10,000 | 2,44,840 |
| Total | 24.87 | 1,46,50,957 | 36,42,97,540 |
Total Application : 12,64,369
| # | Issue Expenses | Est Amt (₹ Cr.) |
|---|---|---|
| 1 | Book Running Lead Managers' fees including underwriting commission | 33.02 |
| 2 | Commission/processing fee for SCSB, Sponsor Banks and Bankers to the Offer. Brokerage, underwriting commission and selling commission and bidding charges for Members of the Syndicate, Registered Brokers, RTAs and CDPs(2)(3)(4)(5) | 5.43 |
| 3 | Fees payable to the Registrar to the Offer | 0.28 |
| 4 | Others | |
| 5 | Auditor, independent chartered accountant, industry expert, intellectual property consultant, etc. | 5.68 |
| 6 | Listing fees, SEBI filing fees, upload fees, BSE & NSE processing fees, book building software fees and other regulatory expenses | 4.84 |
| 7 | Printing and stationery | 1.49 |
| 8 | Advertising and marketing expenses | 5.48 |
| 9 | Fees payable to legal counsels | 9.04 |
| 10 | Miscellaneous | 2.33 |
| Price Details | BSE | NSE |
|---|---|---|
| Final Issue Price | ₹741.00 | ₹741.00 |
| Open | ₹900.05 | ₹900.05 |
| Low | ₹900.00 | ₹900.05 |
| High | ₹987.05 | ₹987.70 |
| Last Trade | ₹941.85 | ₹942.80 |
Concord Biotech IPO is a main-board IPO of 2,09,25,652 equity shares of the face value of ₹1 aggregating up to ₹1,551 Crores. The issue is priced at ₹741 per share. The minimum order quantity is 20.
The IPO opens on Fri, Aug 4, 2023, and closes on Tue, Aug 8, 2023.
MUFG Intime India Pvt.Ltd. is the registrar for the IPO. The shares are proposed to be listed on BSE, NSE.
Zerodha customers can apply online in Concord Biotech IPO using UPI as a payment gateway. Zerodha customers can apply in Concord Biotech IPO by login into Zerodha Console (back office) and submitting an IPO application form.
Steps to apply in Concord Biotech IPO through Zerodha
Visit Zerodha IPO Application Process Review for more detail.
The Concord Biotech IPO opens on Fri, Aug 4, 2023 and closes on Tue, Aug 8, 2023.
Concord Biotech IPO lot size is 20, and the minimum amount required for application is ₹14,820.
You can apply in Concord Biotech IPO online using either UPI or ASBA as a payment method. ASBA IPO application is available in the net banking of your bank account. UPI IPO Application is offered by brokers who don't offer banking services. Read more detail about applying IPO online through Zerodha, Upstox, 5Paisa, Nuvama, HDFC Bank, and SBI Bank.
The finalization of Basis of Allotment for Concord Biotech IPO will be done on Friday, August 11, 2023, and the allotted shares will be credited to your demat account by Thu, Aug 17, 2023. Check the Concord Biotech IPO allotment status.
The Concord Biotech IPO listing date is on Fri, Aug 18, 2023.
